RxDoctor Payments Data

Leah Brancheck, MD

Neurology · Chesterfield, MONPI 1255747119

Payments from drug & device makers

$13,503in general payments, 2019–2025

Across 819 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Pfizer$1K
  • Supernus Pharmaceuticals, Inc.$972
  • Novartis$572
  • UCB, Inc.$501
  • Acadia Pharmaceuticals Inc$409
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$13,486100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)301$4,827
Pfizer154$1,004
Supernus Pharmaceuticals, Inc.22$972
Novartis34$572
UCB, Inc.24$501
Acadia Pharmaceuticals Inc26$409
Amgen19$392
EMD Serono, Inc.14$342
Lundbeck LLC13$292
Teva Pharmaceuticals USA, Inc.15$280
AstraZeneca(2 entities)15$274
Upsher-smith Laboratories LLC12$271
Lilly USA, LLC12$237
Eisai Inc.10$194
SK Life Science, Inc.10$177
Amneal Pharmaceuticals LLC8$173
Biogen10$172
Sunovion Pharmaceuticals Inc.10$147
CSL Behring5$142
Sanofi7$141
Boston Scientific4$119
Neurocrine Biosciences, Inc.5$113
Jazz Pharmaceuticals Inc.3$108
Johnson & Johnson5$107
Medtronic(3 entities)5$90
Abbott4$84
MDD US Operations, LLC3$71
Catalyst Pharmaceuticals, Inc.3$70
Biohaven Pharmaceutical Holding Company Ltd.4$70
Grifols USA, LLC3$67
Microtransponder, Inc.2$65
Biohaven Pharmaceuticals, Inc.3$58
Kyowa Kirin, Inc.4$56
Bausch Health US, LLC3$55
Aprecia Pharmaceuticals, LLC3$53
Akcea Therapeutics, Inc.2$49
Adamas Pharmaceuticals, Inc.3$47
Genentech USA, Inc.3$43
Acorda Therapeutics, Inc3$42
Takeda Pharmaceuticals U.S.A., Inc.1$41
Corium, LLC2$40
Sumitomo Pharma America, Inc.2$40
Ipsen Biopharmaceuticals, Inc2$37
Zyla Life Sciences, Inc.3$37
Banner Life Sciences, LLC2$37
Alnylam Pharmaceuticals Inc.2$33
Azurity Pharmaceuticals, Inc.2$28
Argenx US, Inc.1$25
Bardy Diagnostics, Inc.1$24
Avanir Pharmaceuticals, Inc.1$21
Life Molecular Imaging Ltd1$21
Neurelis, Inc.1$21
Impel Pharmaceuticals Inc.1$20
Sanofi-aventis U.S. LLC1$20
Vertex1$20
Ultragenyx Pharmaceutical Inc.1$19
Avion Pharmaceuticals1$19
Kedrion Biopharma, Inc.1$18
Averitas Pharma Inc.1$18
Axsome Therapeutics, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,503 in reported general payments places this provider in the 70th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$140,454
Medicare patients
630
Services billed
2,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4619$217,788
LamictalLamotrigine18$42,091
Nurtec OdtRimegepant Sulfate23$40,669
QuliptaAtogepant28$31,007
Emgality PenGalcanezumab-Gnlm40$28,875
UbrelvyUbrogepant20$26,295
Ajovy AutoinjectorFremanezumab-Vfrm25$17,629
NuedextaDextromethorphan Hbr/Quinidine11$16,309
EliquisApixaban11$14,232
Carbidopa-LevodopaCarbidopa/Levodopa311$12,465
Lacosamide65$8,354
Levetiracetam173$7,269
Memantine Hcl235$6,555
Clobazam14$6,448
Topiramate138$4,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$67$217,78819 claims
AbbVieQulipta, Ubrelvy$4,827$57,30148 claims
PfizerNurtec Odt, Eliquis, Dilantin$1,004$57,14145 claims
Avanir Pharmaceuticals, Inc.Nuedexta$21$16,30911 claims
Upsher-smith Laboratories LLCTopiramate$271$4,253138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 381 neurology providers in Missouri.

Other neurology in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →